Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals PLC    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
2632(c) 2608(c) 2481(c) 2532(c) 2544(c) Last
601 066 1 909 258 680 485 624 562 401 044 Volume
-0.08% -0.91% -4.87% +2.06% +0.47% Change
More quotes
Financials (USD)
Sales 2020 2 326 M - -
Net income 2020 404 M - -
Net Debt 2020 355 M - -
P/E ratio 2020 20,0x
Yield 2020 1,43%
Sales 2021 2 495 M - -
Net income 2021 426 M - -
Net Debt 2021 126 M - -
P/E ratio 2021 18,7x
Yield 2021 1,58%
Capitalization 7 801 M 7 785 M -
EV / Sales 2020 3,51x
EV / Sales 2021 3,18x
Nbr of Employees 8 600
Free-Float 67,6%
More Financials
Company
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (40.5%); - generic products taken orally (32.6%); - brand name drugs (26.4%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom... 
More about the company
Notations Surperformance© of Hikma Pharmaceuticals PLC
Trading Rating : Investor Rating :
More Ratings
All news about HIKMA PHARMACEUTICALS PLC
12/02SESEN BIO : Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership t..
AQ
11/05HIKMA PHARMACEUTICALS PLC : 3rd quarter results
CO
10/31HIKMA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and v..
CO
10/20HIKMA PHARMACEUTICALS : and Arecor Expand Collaboration
AQ
09/23HIKMA PHARMACEUTICALS : provides update on status of ANDA for generic Advair Dis..
AQ
09/04HIKMA PHARMACEUTICALS : receives favourable court ruling for its generic Vascepa
AQ
09/03HIKMA PHARMACEUTICALS : receives favourable court ruling for its generic Vascepa..
PR
08/31HIKMA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and v..
CO
08/20HIKMA PHARMACEUTICALS PLC : Ex-dividend day for interim dividend
FA
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/07London stocks gain on week; U.S. jobs data, tensions with China weigh
RE
08/07EUROPE : European stocks end week with gains on telecoms, tech boost
RE
More news
News in other languages on HIKMA PHARMACEUTICALS PLC
11/12AVIS D'ANALYSTES DU JOUR : Alcon, BMW, Delivery Hero, Getlink, Logitech, Rubis, ..
09/22AVIS D'ANALYSTES DU JOUR : EDF, Hikma, Innate Pharma, Natixis, Rio Tinto, Roche,..
09/04AVIS D'ANALYSTES DU JOUR : Adyen, Amadeus, Capgemini, Casino, Logitech, Michelin..
08/10LONDON STOCK EXCHANGE : Londres portée par les annonces de Trump
08/10LONDON STOCK EXCHANGE : Londres optimiste sur la reprise économique
More news
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
More recommendations
Stock Trading Strategies
HIKMA PHARMACEUTICALS PLC - 09/09
Technically solid
BUY
More Stock Trading Analysis
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 34,51 $
Last Close Price 33,85 $
Spread / Highest target 18,3%
Spread / Average Target 1,96%
Spread / Lowest Target -43,7%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Henriette Nielsen Executive Vice President-Business Operations
Khalid Walid Hosni Nabilsi Chief Financial Officer
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS PLC27.17%7 785
JOHNSON & JOHNSON1.56%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.9.91%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033